CRO Insights that drive clinical research forward

Check out our poster to dive deeper into the study, understand the methodology, and see the results firsthand.

This article outlines Aixial’s comprehensive best practices for operational oversight of safety system lifecycle management.

At Aixial, we conducted up to 150 neurological studies, up to 300 oncology trials in various geographical areas such as Europe, North America, Asia Pacific, thus giving us the opportunity to oversee what works and what doesn’t work in this field.

Expertise, Scale, and Trust in First-in-Human and Early Development At Aixial, we believe early phase trials—especially first-in-human (FIH) studies—set the…

Sarcomas are a diverse and rare group of malignant tumors arising from mesenchymal tissues, including bone, muscle, fat, and connective tissue.

Brain tumours remain one of the most formidable challenges in medical science due to their complex biology, high morbidity, and limited treatment options.

Q&A with Aixial’s experts at ASCO 2025. Learn how we can drive success in complex oncology trials. Find us at Booth #27150.

Ovarian cancer is one of the most lethal gynecologic malignancies worldwide, often diagnosed at an advanced stage due to subtle or non-specific symptoms.

Monoclonal antibodies (mAbs) have revolutionized the landscape of neurodegenerative disease research…

On April 11, World Parkinson’s Day, we are reminded of the importance of research in improving treatments and finding a cure.

In the European Union, a rare disease is defined as one affecting fewer than 5 out of 10,000 members of the general population…

The field of CGT is revolutionizing modern medicine, offering potential curative treatments for diseases previously considered untreatable…